Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but the Conestoga Small Cap Composite underperformed the Russell 2000 Growth Index, returning -1.4% compared to the Index's 12.2% gain [1] - The gains in the Russell 2000 Growth Index were primarily driven by low-quality stocks, particularly unprofitable, high-beta names [1] Company Analysis: Simulations Plus, Inc. (NASDAQ:SLP) - Simulations Plus, Inc. specializes in drug discovery and development software that leverages AI and machine learning for modeling and simulation [2] - The stock had a one-month return of 0.98% but experienced a significant decline of 54.90% over the past 52 weeks, closing at $15.40 per share with a market capitalization of $309.957 million on October 17, 2025 [2] - The company has faced slowing revenue growth due to funding pressures on smaller biotech customers, which has reduced demand for its products [3] - Despite its potential, the valuation of Simulations Plus remains elevated compared to peers, raising concerns about risk/reward dynamics [3] - Increased competition in drug-modeling software and inconsistent performance in consulting services may further pressure the company's margins [3] - Conestoga Capital Advisors decided to sell the stock due to near-term headwinds outweighing long-term potential [3] Hedge Fund Interest - Simulations Plus, Inc. was held by 11 hedge fund portfolios at the end of Q2 2025, a decrease from 13 in the previous quarter [4] - While acknowledging the potential of Simulations Plus, the company believes that other AI stocks present greater upside potential with less downside risk [4]